Guangdong Taiankang Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 5th Board of Directors' 18th Meeting
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed in this announcement, and that there are no false records, misleading statements, or significant omissions.
I. Convening of the Meeting
The 18th meeting of the 5th Board of Directors of Guangdong Taiankang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") (hereinafter referred to as the "Meeting") was notified to all directors by written delivery or email on June 9, 2026. The meeting was held via teleconference on June 12, 2026. The meeting was convened and presided over by Chairman Mr. Zheng Hanjie. There were 7 directors eligible to attend, and 7 directors actually attended. All senior management personnel were present at the meeting.
The convening and holding of this Board meeting comply with the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Articles of Association of Guangdong Taiankang Pharmaceutical Co., Ltd." (hereinafter referred to as the "Articles of Association"), and other regulations. The resolutions of the meeting are legal and valid.
II. Review of Matters by the Board of Directors
After full discussion by the attending directors, the proposals reviewed at this meeting are as follows:
(I) Deliberation and Approval of the "Proposal on Adjusting the Company's Plan for Issuing Convertible Corporate Bonds to Unspecified Targets"
In accordance with the "Company Law," "Securities Law," "Administrative Measures for the Registration of Issuance of Securities by Listed Companies" (hereinafter referred to as the "Registration Measures") and other laws, regulations, and normative documents, as well as the authorization granted by the Company's 202_ Annual General Meeting of Shareholders to the Board of Directors, the Company has adjusted the issuance size and the use of proceeds for the current plan to issue convertible corporate bonds to unspecified targets based on the actual situation. The details are as follows:
(1) Issuance Size
Before adjustment:
Based on the requirements of relevant laws, regulations, and normative documents and the Company's specific situation, the total amount of funds to be raised by issuing convertible bonds shall not exceed RMB 870,000,000,000 (inclusive). The specific issuance size shall be determined by the Company's shareholders' meeting authorizing the Company's Board of Directors (or authorized personnel) within the aforementioned limit.
After adjustment:
Based on the requirements of relevant laws, regulations, and normative documents and the Company's specific situation, the total amount of funds to be raised by issuing convertible bonds shall not exceed RMB 80,100,000,000 (inclusive). The specific issuance size shall be determined by the Company's shareholders' meeting authorizing the Company's Board of Directors (or authorized personnel) within the aforementioned limit.
Voting results: 7 votes in favor, 0 votes against, 0 abstentions.
(2) Use of Proceeds from this Issuance
The total amount of funds to be raised by issuing convertible bonds to unspecified targets is expected not to exceed RMB 87,000,000,000 (inclusive). After deducting issuance expenses, the net proceeds from the issuance will be invested in the following projects: